| Ca(2+) channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in hypertensive rats. | |
| | |
MedLine Citation:
|
PMID: 20543715 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The beneficial cardiac effects of some Ca(2+) channel blockers have been attributed to blood pressure reduction, but these pleiotropic effects require further investigation. We compared the effects of benidipine, which has beneficial cardiac effects, and nitrendipine, which does not, in an animal model of hypertensive diastolic heart failure (DHF). METHODS AND RESULTS: Male Dahl salt-sensitive rats were fed a high-salt diet from age 7 weeks to induce hypertension and were either vehicle or orally administered benidipine (3 mg/kg daily) or nitrendipine (10 mg/kg daily) from age 10 to 18 weeks. Control rats were maintained on a low-salt diet. In vehicle-treated rats, left-ventricular (LV) fractional shortening was preserved but LV end-diastolic pressure was increased, indicative of DHF. Benidipine and nitrendipine had similar antihypertensive effects and reduced both LV weight and cardiomyocyte hypertrophy. Benidipine reduced LV diastolic stiffness and mortality to a greater extent than did nitrendipine. Benidipine, but not nitrendipine, also reduced lung weight. The extent of interstitial fibrosis and the abundance of mRNAs for prohypertrophic, profibrotic, or proinflammatory genes in the left ventricle were reduced by benidipine and nitrendipine. Benidipine, but not nitrendipine, increased capillary density and restored the expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and endothelial nitric oxide synthase in the left ventricle. CONCLUSIONS: Benidipine reduced LV diastolic stiffness and increased survival, effects likely attributable predominantly to promotion of coronary angiogenesis rather than to attenuation of interstitial fibrosis. Benidipine may thus be more effective than purely L-type Ca(2+) channel blockers in preventing hypertensive DHF. |
| | |
Authors:
|
Takao Nishizawa; Xian Wu Cheng; Zhehu Jin; Koji Obata; Kohzo Nagata; Akihiro Hirashiki; Takeshi Sasaki; Akiko Noda; Kyosuke Takeshita; Hideo Izawa; Guo-Ping Shi; Masafumi Kuzuya; Kenji Okumura; Toyoaki Murohara |
Related Documents
:
|
15488085 - Maximal longitudinal contraction velocity in assessment of left ventricular systolic fu... 12100905 - An alternative to left ventricular volume reduction. 11875385 - Quantification of left ventricular diastolic pressure-volume relations during routine c... 2301255 - Left atrial function in acute transient left ventricular ischemia produced during percu... 16770025 - Proton tonometer determination of intraocular pressure in patients with scarred corneas. 3038745 - Decreased intraocular pressure in dogs with one-kidney, one wrapped hypertension. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of hypertension Volume: 28 ISSN: 1473-5598 ISO Abbreviation: J. Hypertens. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-06-24 Completed Date: 2010-12-17 Revised Date: 2011-07-27 |
Medline Journal Info:
|
Nlm Unique ID: 8306882 Medline TA: J Hypertens Country: England |
Other Details:
|
Languages: eng Pagination: 1515-26 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antihypertensive Agents / pharmacology, therapeutic use Calcium Channel Blockers / pharmacology* Coronary Circulation / drug effects* Diastole / drug effects Dihydropyridines / pharmacology* Heart Failure / drug therapy, metabolism, physiopathology Heart Ventricles / drug effects*, metabolism, physiopathology Hypertension / drug therapy*, mortality, physiopathology Male Neovascularization, Physiologic / drug effects* Nitrendipine / pharmacology, therapeutic use Rats Rats, Inbred Dahl |
| Grant Support | |
ID/Acronym/Agency:
|
R01 HL060942-12/HL/NHLBI NIH HHS; R01 HL081090-04/HL/NHLBI NIH HHS; R01 HL088547-04/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Dihydropyridines; 105979-17-7/benidipine; 39562-70-4/Nitrendipine |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A new approach to assessing the structural total peripheral resistance amplifier in renal (Page) hyp...
Next Document: Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidenc...